Orasure Technologies IncOSUR
What Orasure Technologies Inc does.
OTI transforms health through actionable insight and decentralizes diagnostics to connect people to healthcare wherever they are.
Our products and services reside under one reporting hierarchy, with commercial and innovation teams, which are part of a single business unit covering multiple product lines. Our business is principally comprised of the development, manufacture, marketing, sale and distribution of (i) diagnostics products, and (ii) sample management solutions.
In November 2025, the Company acquired BioMedomics, Inc. ("BioMedomics"). BioMedomics' SickleSCAN ® test is the world's first rapid point-of-care test for sickle cell disease. The SickleSCAN ® test is currently sold in markets outside the U.S.
Revenue and profit, by fiscal year.
| Fiscal year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | $171.7M | $233.7M | $387.5M | $405.5M | $185.8M | $115.0M |
| Net income | -$14.9M | -$23.0M | -$17.1M | $53.7M | -$19.5M | -$68.7M |
| Free cash flow | -$20.9M | -$57.3M | -$54.0M | $135.8M | $23.6M | -$53.2M |
More on OSUR.
- Orasure Technologies Inc summary
- Orasure Technologies Inc financial statements
- Orasure Technologies Inc key metrics
- Orasure Technologies Inc health scores and style box
- Orasure Technologies Inc earnings
- Orasure Technologies Inc dividends
- Orasure Technologies Inc valuation
- Orasure Technologies Inc ownership and insiders
- Orasure Technologies Inc peers
Figures from Orasure Technologies Inc's filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.